Last week’s MM&M webcast titled “From Selling Pills to Selling Health Outcomes” was packed with thought provoking material. Joining the podcast were Daniel Hawkins (Clarion Healthcare Consulting), Dennis Urbaniak (Sanofi-Aventis) and Dan Rubin (inVentiv Patient …
Read the full story »
The first generics casualty of the financial crisis was Ratiopharm which is now being sold my the Merckle family to make up for their recent stock market losses. Now Actavis, the fifth largest generics company …
Although we’ve seen a huge increase in the number of clients going straight to purchasing white-label formulations products, basically the switch for European generics companies from manufacturing to marketing, CEE markets still have low manufacturing …
